Tvardi Therapeutics
TVRD
160 hedge funds and large institutions have $354M invested in Tvardi Therapeutics in 2022 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 56 increasing their positions, 42 reducing their positions, and 20 closing their positions.
105% more call options, than puts
Call options by funds: $1.51M | Put options by funds: $734K
33% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 42
9% more capital invested
Capital invested by funds: $324M → $354M (+$30M)
0.03% less ownership
Funds ownership: 1.79% → 1.76% (-0.03%)
3% less funds holding
Funds holding: 165 → 160 (-5)
20% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$6.44M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
+$2.54M |
| 3 |
BlackRock
New York
|
+$1.59M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$727K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$696K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$4.49M |
| 2 |
JP Morgan Chase
New York
|
-$2.95M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$2.5M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.17M |
| 5 |
AWCI
Alpine Woods Capital Investors
Purchase,
New York
|
-$1.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GC
176
Guggenheim Capital
Chicago,
Illinois
| – | -$99K | -294 | Closed |
|
|
VRS
177
Virginia Retirement Systems
Richmond,
Virginia
| – | -$97.3K | -289 | Closed |
|
|
MOACM
178
Mutual of America Capital Management
New York
| – | -$84K | -249 | Closed |
|
179
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$14K | -27 | Closed |
|
|
BHWM
180
Beaird Harris Wealth Management
Dallas,
Texas
| – | -$1K | -2 | Closed |
|
TVRD Hedge Fund Activity: Q4 2022 in Review
160 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q4 2022, worth a combined $354M — up 9.3% from $324M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of TVRD and 16 opened new positions — a net loss of 4 holders — while 42 trimmed existing stakes and 56 added.
The largest buyer was Bank of America, adding an estimated $6.44M. The largest seller was Farallon Capital Management, cutting an estimated $4.49M.
- 160 institutional investors held Tvardi Therapeutics (TVRD) as of Q4 2022, down from 165 in Q3 2022.
- Funds reported $354M of Tvardi Therapeutics stock for Q4 2022, up 9.3% quarter-over-quarter.
- 16 funds opened new Tvardi Therapeutics positions in Q4 2022 and 20 closed out, a net change of -4 holders.
- The largest Tvardi Therapeutics buyer in Q4 2022 was Bank of America, an estimated $6.44M added.
- The largest Tvardi Therapeutics seller in Q4 2022 was Farallon Capital Management, an estimated $4.49M sold.
Based on aggregated 13F filings for Q4 2022.